Defective MHC class II expression in an MHC class II deficiency patient is caused by a novel deletion of a splice donor site in the MHC class II transactivator gene

Immunogenetics

Volumn 51, Issue 1, 2000, Pages 42-49

  Peijnenburg, Ad ^a   Van Den Berg, Rian ^a   Van Eggermond, Marja J C A ^a   Sanal, Özden ^b   Vossen, Jaak M J J ^a   Lennon, Ana Maria ^c   Alcaïde Loridan, Catherine ^c   Van Den Elsen, Peter J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HACETTEPE UNIVERSITY   (Turkey)

^c INSTITUT PASTEUR   (France)

Author keywords

Bare lymphocyte syndrome; Gene regulation; Immunodeficiency; MHC class II deficiency; MHC class II transactivator (CIITA)

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; TRANSACTIVATOR PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; BARE LYMPHOCYTE SYNDROME; CASE REPORT; CELL FUSION; CONTROLLED STUDY; GENE DELETION; GENETIC COMPLEMENTATION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; PRIORITY JOURNAL; TRANSACTIVATION;

EID: 0034016674     PISSN: 00937711     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002510050007     Document Type: Article

References (35)

1. Bontron S, Ucla C, Mach B, Steimle V (1997a) Efficient repression of endogenous major histocompatibility complex class II expression through dominant negative CIITA mutants isolated by functional selection strategy. Mol Cell Biol 17:4249-4258
2. Bontron S, Steimle V, Ucla C, Mach B (1997b) Two novel mutations in the MHC class II transactivator CIITA in a second patient from MHC class II deficiency complementation group A. Hum Genet 99:541-546
3. Boss JM (1997) Regulation of transcription of MHC class II genes. Curr Opin Immunol 9:107-113
4. Brown JA, He XF, Westerheide SD, Boss JM (1996) Characterization of the expressed CIITA allele in the class II MHC transcriptional mutant RJ2.2.5. Immunogenetics 43:88-91
5. Brown JA, Rogers EM, Boss JM (1998) The MHC class II transactivator (CIITA) requires conserved leucine charged domains for interactions with the conserved W box promoter element. Nucleic Acids Res 26:4128-4136
6. Chen C, Okayama H (1987) High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 7:2745-2752
7. Chin K-C, Li G, Ting JP-Y (1997a) Importance of acidic, proline/ serine/threonine-rich, and GTP-binding regions in the major histocompatibility complex class II transactivator: generation of transdominant-negative mutants. Proc Natl Acad Sci USA 94:2501-2506
8. Chin K-C, Li G, Ting JP-Y (1997b) Activation and transdominant suppression of MHC class II and HLA-DMB promoters by a series of C-terminal class II transactivator deletion mutants. J Immunol 159:2789-2794
9. Durand B, Sperisen P, Emery P, Barra E, Zufferey M, Mach B, Reith W (1997) RFXAP, a novel subunit of the RFX DNA binding complex is mutated in class II deficiency. EMBO J 16:1045-1055
10. II32. Nucleic Acids Res 25:2522-2528
11. Gobin SJP, Peijnenburg A, Keijsers V, Van den Elsen PJ (1997) Site α is crucial for two routes of IFN-γ-induced MHC class I transactivation: the ISRE-mediated route and a novel pathway involving CIITA. Immunity 6:601-611
12. Gobin SJP, Peijnenburg A, Van Eggermond M, Van Zutphen M, Van den Berg R, Van den Elsen PJ (1998) The RFX complex is crucial for the constitutive and CIITA-mediated transactivation of MHC class I and β2-microglobulin genes. Immunity 9:531-541
13. Kobe B, Deisenhofer J (1995) Proteins with leucine-rich repeats Curr Opin Struct Biol 5:409-416
14. Lennon AM, Ottone C, Rigaud G, Deaven LL, Longmire J, Fellous M, Bono R, Alcaide-Loridan C (1997) Isolation of a B-cell-specific promoter for the human class II transactivator. Immunogenetics 45:266-273
15. Lisowska-Grospierre B, Fondaneche M-C, Rolls M-P, Griscelli C, Fischer A (1994) Two complementation groups account for most cases of inherited MHC class II deficiency. Hum Mol Genet 3:953-958
16. Mach B, Steimle V, Martinez-Soria E, Reith W (1996) Regulation of MHC class II genes: lessons from a disease. Annu Rev Immunol 14:301-331
17. Mahanta SK, Scholl T, Yang FC, Strominger JL (1997) Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein. Proc Natl Acad Sci USA 94:6324-6329
18. Martin B, Chin K-C, Olsen JC, Skinner CA, Dey A, Ozato K, Ting JP-Y (1997) Induction of MHC class I expression by the MHC class II transactivator CIITA. Immunity 6:591-600
19. Masternak K, Barras E, Zufferey M, Conrad B, Corthals G, Aebersold R, Sanchez J-C, Hochstrasser DF, Mach B, Reith W (1998) A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat Genet 20:273-277
20. Nagarajan UM, Louis-Plence P, DeSandro A, Nilsen R, Bushey A, Boss JM (1999) RFX-B is the gene responsible for the most common cause of the bare lymphocyte syndrome, a MHC class II immunodeficiency. Immunity 10:153-162
21. Peijnenburg A, Godthelp B, Van Boxel-Dezaire A, Van den Elsen PJ (1995) Definition of a novel complementation group in MHC class II deficiency. Immunogenetics 41:287-294
22. Peijnenburg A, Gobin SJP, Van Eggermond MCJA, Godthelp BC, Van Graafeiland N, Van den Elsen PJ (1997) Introduction of exogenous class II transactivator in MHC class II-deficient ABI fibroblasts results in incomplete rescue of MHC class II antigen expression. J Immunol 159:2720-2727
23. Peijnenburg A, Van Eggermond MCJA, Van den Berg R, Sanal O, Vossen JMJJ, Van den Elsen PJ (1999) Molecular analysis of an MHC class II deficiency patient reveals a novel mutation in the RFX5 gene. Immunogenetics 49:338-345
24. Rebai N, Malissen B, Pierres M, Acolla RS, Corte G, Mawas C (1983) Distinct HLA-DR epitopes and distinct families of HLA-DR molecules defined by 15 monoclonal antibodies either DR or allo-anti-Ia crossreacting with human DR. Eur J Immunol 13:106-111
25. Riley JL, Westerheide SD, Price JA, Brown JA, Boss JM (1995) Activation of class II MHC genes requires both the X box region and the class II transactivator (CIITA). Immunity 2:533-543
26. Scholl T, Mahanta SK, Strominger JL (1997) Specific complex formation between the type II bare lymphocyte syndrome-associated transactivator CIITA and RFX5. Proc Natl Acad Sci USA 94:6330-6334
27. Sims TN, Elliott JF, Ramassar V, Denney DW, Halloran PF (1997) Mouse class II transactivator: cDNA sequence and amino acid comparison with the human class II transactivator. Immunogenetics 45:220-222
28. Spits H, Borst J, Giphart MJ, Coligan J. Terhorst CP, De Vries JE (1984) HLA-DC antigens can serve as recognition elements for human cytotoxic T lymphocytes. Eur J Immunol 14:299-304
29. Steimle V, Otten LA, Zufferey M, Mach B (1993) Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 75:135-146
30. Steimle V, Durand B, Barras E, Zufferey M, Hadam MR, Mach B, Reith W (1995) A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev 9:1021-1032
31. Vandekerckhove BAE, Datema G, Koning F, Goulmy E, Persijn GG, Van Rood JJ, Claas FHJ, De Vries JE (1990) Analysis of the donor-specific cytotoxic T lymphocyte repertoire in a patient with a long term surviving allograft. J Immunol 144:1288-1294
32. Verduyn W, Doxiadis IIN, Anholts J, Drabbels JJM, Naipal A, D'Amaro J, Persijn GG, Giphart MJ, Schreuder GM (1993) Biotinylated DRB sequence-specific oligonucleotides: comparison to serologic HLA-DR typing of organ donors in Eurotransplant. Hum Immunol 37:59-67
33. Yun S, Gustafsson K, Fabre JW (1997) Suppression of MHC class II expression by human class II trans-activator constructs lacking the N-terminal domain. Int Immunol 9:1545-1553
34. Zhou H, Glimcher LH (1995) Human MHC class II gene transcription directed by the carboxyl terminus of CIITA, one of the defective genes in type II MHC combined immune deficiency. Immunity 2:545-553
35. Zhou H, Su HS, Zhang X, Douhan III J, Glimcher LH (1997) CIITA-dependent and -independent class II MHC expression revealed by a dominant negative mutant. J Immunol 158:4741-4749